干细胞移植治疗脑出血的关键影响因素研究进展

摘要/Abstract

摘要：

近年脑出血的干细胞治疗策略因其良好的前景吸引了越来越多基础和临床研究工作者的兴趣。临床前研究表明移植诸如胚胎干细胞、诱导多能干细胞、神经干细胞和间充质干细胞等均可获得不错的疗效，并揭示了脑出血后干细胞移植治疗起效的可能机制有细胞替代、神经营养与保护、促血管生成、免疫炎症反应调节等。尽管临床研究也表明干细胞治疗脑出血安全有效，但影响干细胞移植治疗的几大关键因素尚未确定，例如移植的细胞类型、细胞数量、移植时间、最佳给药途径、最佳受众人群以及如何追踪细胞等。本文根据最新研究成果就以上关键影响因素的研究进展作一综述，为后续研究提供有价值的参考。

文章导读： 本文分别对影响干细胞治疗的细胞数量、移植时间、最佳给药途径等关键问题展开阐述，以供后续研究参考。

关键词: 脑出血; 干细胞; 关键因素

Abstract:

In recent years, stem cell-based approaches have attracted more attention from scientists and clinicians due to their possible therapeutical effect on intracerebral hemorrhage(ICH). Preclincal studies have demonstrated that the beneficial effects of stem cells on ICH. The stem cells include embryonic stem cells(ESCs), inducible pluripotent stem cells(iPSCs), neural stem cells (NSCs), and mesenchymal stem cell(MSCs). Their underlying mechanisms might be due to cell replacement, neurotrophic and neuroprotection, angiogenesis, and modulation on inflammation and immune response. Although several clinical studies have shown the high efficiency and safety of stem cell in ICH management, some key factors such stem cell type, cell dose, time window, and optimal cell transplantation approach remain to be addressed. According to the latest researches, this paper summarizes the advances in terms of these factors to provide a valuable reference for future research.

Key words: Intracranial hemorrhage; Stem cell; Key factors

张倩，胡荣，郑江，冯华. 干细胞移植治疗脑出血的关键影响因素研究进展[J]. 中国卒中杂志, 2015, 10(10): 890-895.

ZHANG Qian, HU Rong, ZHENG Jiang, et al.. Progress in Key Influence Factors of Stem Cell Transplantation for the Treatment of Intracerebral Hemorrhage[J]. Chinese Journal of Stroke, 2015, 10(10): 890-895.

参考文献

1 Jeong H, Yim HW, Cho YS, et al. Efficacy and safety

of stem cell therapies for patients with stroke:a

systematic review and single arm meta-analysis[J]. Int

J Stem Cells, 2014, 7:63-69.

2 Sullivan R1, Duncan K, Dailey T, et al. A possible

new focus for stroke treatment-migrating stem cells[J].

Expert Opin Biol Ther, 2015, 15:949-958.

3 Mendelow AD, Gregson BA, Rowan EN, et al.

Early surgery versus initial conservative treatment

in patients with spontaneous supratentorial lobar

intracerebral haematomas (STICH Ⅱ):a randomised

trial[J]. Lancet, 2013, 382:397-408.

4 Qin J, Gong G, Sun S, et al. Functional recovery aftertransplantation of induced pluripotent stem cells in a

rat hemorrhagic stroke model[J]. Neurosci Lett, 2013,

554:70-75.

5 Nam H, Lee KH, Nam DH, et al. Adult human neural

stem cell therapeutics:Current developmental status

and prospect[J]. World J Stem Cells, 2015, 7:126-136.

6 Shinozuka K, Dailey T, Tajiri N, et al. Stem cell

transplantation for neuroprotection in stroke[J]. Brain

Sci, 2013, 3:239-261.

7 Locatelli F, Bersano A, Ballabio E, et al. Stem cell

therapy in stroke[J]. Cell Mol Life Sci, 2009, 66:757-772.

8 Stroemer P, Patel S, Hope A, et al. The neural stem

cell line CTX0E03 promotes behavioral recovery and

endogenous neurogenesis after experimental stroke

in a dose-dependent fashion[J]. Neurorehabil Neural

Repair, 2009, 23:895-909.

9 Lee ST, Chu K, Jung KH, et al. Anti-inflammatory

mechanism of int ravascular neural stem cell

transplantation in haemorrhagic stroke[J]. Brain,

2008, 131:616-629.

10 Banerjee S, Williamson DA, Habib N, et al. The

potential benefit of stem cell therapy after stroke:an

update[J]. Vasc Health Risk Manag, 2012, 8:569-580.

11 Taguchi A, Soma T, Tanaka H, et al. Administration

of CD34+ cells after stroke enhances neurogenesis via

angiogenesis in a mouse model[J]. J Clin Invest, 2004,

114:330-338.

12 Hu S, Rotschafer JH, Lokensgard JR, et al. Activated

CD8+ T lymphocytes inhibit neural stem/progenitor

cell proliferation:role of interferon-gamma[J]. PLoS

One, 2014, 9:e105219.

13 Hicks AU, MacLellan CL, Chernenko GA, et al. Longterm

assessment of enriched housing and subventricular

zone derived cell transplantation after focal ischemia in

rats[J]. Brain Res, 2008, 1231:103-112.

14 Smith EJ, St roemer RP, Gorenkova N, et al.

Implantation site and lesion topology determine

efficacy of a human neural stem cell line in a rat model

of chronic stroke[J]. Stem Cells, 2012, 30:785-796.

15 Meamar R, Dehghani L, Ghasemi M, et al. Stem Cell

Therapy in Stroke:A Review Literature[J]. Int J Prev

Med, 2013, 4:139-146.

16 Yang B, Strong R, Sharma S, et al. Therapeutic time

window and dose response of autologous bone marrow

mononuclear cells for ischemic stroke[J]. J Neurosci

Res, 2011, 89:833-839.

17 Darsalia V, Allison SJ, Cusulin C, et al. Cell number

and timing of transplantation determine survival of

human neural stem cell grafts in stroke-damaged rat

brain[J]. J Cereb Blood Flow Metab, 2011, 31:235-242.

18 Savitz SI, Chopp M, Deans R, et al. Stem CellTherapy as an Emerging Paradigm for Stroke (STEPS)

Ⅱ[J]. Stroke, 2011, 42:825-829.

19 Fischer UM, Harting MT, Jimenez F, et al. Pulmonary

passage is a major obstacle for intravenous stem cell

delivery:the pulmonary first-pass effect[J]. Stem Cells

Dev, 2009, 18:683-692.

20 Andres RH, Guzman R, Ducray AD, et al. Cell

replacement therapy for intracerebral hemorrhage[J].

Neurosurg Focus, 2008, 24:E16.

21 Zhang W, Yan Q, Zeng YS. Implantation of adult bone

marrow-derived mesenchymal stem cells transfected

with the neurotrophin-3 gene and pretreated with

retinoic acid in completely transected spinal cord[J].Brain Res, 2010, 1359:256-271.

22 Nakagomi N, Nakagomi T, Kubo S, et al. Endothelial

cells support survival, proliferation, and neuronal

differentiation of transplanted adult ischemiainduced

neural stem/progenitor cells after cerebral

infarction[J]. Stem Cells, 2009, 27:2185-2195.

23 Bliss TM, Andres RH, Steinberg GK. Optimizing the

success of cell transplantation therapy for stroke[J].

Neurobiol Dis, 2010, 37:275-283.

24 Barbosa da Fonseca LM, Gutfilen B, Rosado de Castro

PH, et al. Migration and homing of bone-marrow

mononuclear cells in chronic ischemic stroke after intraarterial

injection[J]. Exp Neurol, 2010, 221:122-128.

[1]	郑占军, 赵性泉. 脑小血管病影像学标志物与自发性高血压脑出血的相关性研究进展[J]. 中国卒中杂志, 2022, 17(12): 1396-1402.
[2]	程实, 李静, 郭军平, 胡爱香, 于鑫玮, 韩玮, 梁瑛, 张越巍, 冀瑞俊. 急性卒中患者住院期间感染的临床特征及危险因素分析[J]. 中国卒中杂志, 2022, 17(10): 1065-1070.
[3]	范琳琳, 田飞. 以癫痫持续状态和脑出血为特征的胶质母细胞瘤1例并文献复习[J]. 中国卒中杂志, 2022, 17(09): 1002-1006.
[4]	王拥军, 李子孝, 谷鸿秋, 翟屹, 姜勇, 周齐, 赵性泉, 王伊龙, 杨昕, 王春娟, 孟霞, 李昊, 刘丽萍, 荆京, 吴静, 徐安定, 董强, David Wang, 王文志, 马旭东, 赵继宗, 《中国卒中报告》编写委员会（第一作者）. 中国卒中报告2020（中文版）（3）[J]. 中国卒中杂志, 2022, 17(07): 675-682.
[5]	宋新杰, 姜睿璇, 张怡君, 王安心, 李子孝, 赵性泉. 脑出血急性期不同血压参数与预后的关系[J]. 中国卒中杂志, 2022, 17(07): 769-773.
[6]	王拥军, 李子孝, 谷鸿秋, 翟屹, 姜勇, 周齐, 赵性泉, 王伊龙, 杨昕, 王春娟, 孟霞, 李昊, 刘丽萍, 荆京, 吴静, 徐安定, 董强, David Wang, 王文志, 马旭东, 赵继宗, 《中国卒中报告》编写委员会（第一作者）. 中国卒中报告2020（中文版）（2）[J]. 中国卒中杂志, 2022, 17(06): 553-567.
[7]	宋新杰, 王安心, 李子孝, 赵性泉. 下肢深静脉血栓形成与脑出血患者预后的关系研究[J]. 中国卒中杂志, 2022, 17(06): 634-637.
[8]	王拥军, 李子孝, 谷鸿秋, 翟屹, 姜勇, 周齐, 赵性泉, 王伊龙, 杨昕, 王春娟, 孟霞, 李昊, 刘丽萍, 荆京, 吴静, 徐安定, 董强, David Wang, 王文志, 马旭东, 赵继宗, 《中国卒中报告》编写委员会（第一作者）. 中国卒中报告2020（中文版）（1）[J]. 中国卒中杂志, 2022, 17(05): 433-447.
[9]	张冬雪, 邹伟. 外泌体对缺血性卒中的作用机制及研究进展[J]. 中国卒中杂志, 2022, 17(04): 418-425.
[10]	刘欣瑶, 毕京凤, 张英魁. 脑出血信号改变机制与磁共振影像表现[J]. 中国卒中杂志, 2021, 16(12): 1217-1221.
[11]	冯皓, 王鑫, 王文娟, 赵性泉. 不同性别老年脑出血患者血脂水平与预后的关系研究[J]. 中国卒中杂志, 2021, 16(10): 1016-1022.
[12]	陈晴晴, 孙金菊, 周雪姣. 急性脑出血继发院内消化道出血的影响因素分析[J]. 中国卒中杂志, 2021, 16(10): 1029-1033.
[13]	徐昳, 陈淑芬, 韩翔. 感染性心内膜炎合并脑出血伴多器官梗死1例[J]. 中国卒中杂志, 2021, 16(08): 774-778.
[14]	王丹丹, 王晶, 王安心, 张怡君, 赵性泉. 超敏C反应蛋白与新发脑出血关系研究[J]. 中国卒中杂志, 2021, 16(07): 664-669.
[15]	王振, 徐伟, 贺国华, 胡珏, 冯铁桥, 童洋萍, 徐桂兰, 肖慧, 易海波, 宋治. 急性缺血性卒中静脉溶栓后远隔部位脑出血的临床特征和预后分析[J]. 中国卒中杂志, 2021, 16(07): 680-686.